Skip to main content
HCPCS J9073 · Level II · Part B drug

J9073: cyclophosphamide, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9073

Billing unit
5 MG
Inj cyclophos dr reddys 5 mg
ASP payment limit
$0.465
October 2026; -6.6% vs July 2026
Practitioner MUE
1500
MAI 3
OPPS status
SI K
APC 0741
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9073 is the Level II code for Injection, cyclophosphamide (dr. reddy's), 5 mg, billed per 5 MG. The Medicare Part B ASP payment limit for October 2026 is $0.465 per billing unit, down 6.6% from July 2026. The practitioner MUE allows up to 1500 units per date of service (MAI 3), so a full 1500-unit day is $697.50 at the current limit. Under OPPS it carries status indicator K in APC 0741. J9073 is billed in units of 5 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names cyclophosphamide: J9072 (Frindovyx from Avyxa Pharma, LLC); J9074 (the Sandoz product (manufacturer named in its CMS descriptor)); J9071 (the Auromedics product (manufacturer named in its CMS descriptor)); J9075 (not otherwise specified (for products without their own code)); J9076 (the Baxter product (manufacturer named in its CMS descriptor)). The ASP crosswalk maps 9 NDCs to it, sold as Cyclophosphamide (Ingenus), Cyclophosphamide by Ingenus Pharmaceuticals LLC, BluePoint Laboratories, Athenex Pharmaceutical Division, LLC. No current Billing and Coding Article lists J9073, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9073 at $0.465 per 5 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.498 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9073
QuarterPayment limitPerCoinsurance
October 2026$0.4655 MG20%
July 2026$0.4985 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 9 NDCs from 4 labelers to J9073. Report the NDC in the claim's drug segment and bill the number of J9073 units that equals the quantity administered divided by 5 MG; the last column gives units per full package.

NDCs that crosswalk to J9073
NDCDrug nameLabelerPackage sizeBilling units / package
50742-0519-02Cyclophosphamide (Ingenus)Ingenus Pharmaceuticals LLC2.5 × 1100
50742-0520-05Cyclophosphamide (Ingenus)Ingenus Pharmaceuticals LLC5 × 1200
50742-0521-10Cyclophosphamide (Ingenus)Ingenus Pharmaceuticals LLC10 × 1400
68001-0564-22CyclophosphamideBluePoint Laboratories5 × 1200
68001-0565-28CyclophosphamideBluePoint Laboratories10 × 1400
70860-0218-10CyclophosphamideAthenex Pharmaceutical Division, LLC10 × 1400
75907-0189-35CyclophosphamideDr. Reddy's Laboratories Inc.10 × 1400
75907-0190-07CyclophosphamideDr. Reddy's Laboratories Inc.5 × 1200
75907-0191-02CyclophosphamideDr. Reddy's Laboratories Inc.2.5 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9073. For practitioners the limit is 1500 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9073 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services15003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital15003 Date of Service Edit: ClinicalPrescribing Information
DME supplier15003 Date of Service Edit: ClinicalPrescribing Information

MUE for J9073 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9073 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9073 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9073 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9073 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9073 carries status indicator K and is assigned to APC 0741, with a published national unadjusted payment of $0.465. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9073 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $0.47 per 5 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9073 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9073

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9073

What does HCPCS code J9073 describe?

J9073 is defined by CMS as "Injection, cyclophosphamide (dr. reddy's), 5 mg". Each billing unit represents 5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9073 a CPT code?

No. J9073 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as cyclophosphamide; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9073 reports the drug itself in 5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9073 in October 2026?

The ASP-based payment limit is $0.465 per 5 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.498. Commercial payers use their own fee schedules.

How many units of J9073 can be billed per day?

The practitioner Medically Unlikely Edit is 1500 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9073?

The October 2026 ASP crosswalk lists 9 NDCs from 4 labelers: Cyclophosphamide (Ingenus) (Ingenus Pharmaceuticals LLC); Cyclophosphamide (BluePoint Laboratories); Cyclophosphamide (Athenex Pharmaceutical Division, LLC); Cyclophosphamide (Dr. Reddy's Laboratories Inc.). For example NDC 50742-0519-02 (package size 2.5) equals 100 billing units of J9073.

Does J9073 have NCCI bundling edits?

No active practitioner PTP pairs list J9073 as a column-1 or column-2 code in the v323r0 release.

J9073 vs J9072: what is the difference?

Both are HCPCS Level II codes whose descriptor names cyclophosphamide. What sets J9072 apart: Frindovyx from Avyxa Pharma, LLC. J9073 is billed per 5 mg, limit $0.465, MUE 1500; J9072 is billed per 5 mg, limit $8.12, MUE 1500. Report the code whose descriptor matches the product and setting in the record.

J9073 vs J9074: what is the difference?

Both are HCPCS Level II codes whose descriptor names cyclophosphamide. What sets J9074 apart: the Sandoz product (manufacturer named in its CMS descriptor). J9073 is billed per 5 mg, limit $0.465, MUE 1500; J9074 is billed per 5 mg, limit $3.238, MUE 1500. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.